Products for Research Use Only

Miransertib

CAT: 0804-HY-19719-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19719-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research[1]. Miransertib is effective against Leishmania[2].
CAS Number
1313881-70-7
Product Name Alternative
ARQ-092
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
Akt; Parasite
Type
Reference compound
Related Pathways
Anti-infection; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Infection
Assay Protocol
https://www.medchemexpress.com/ARQ-092.html
Concentration
10mM
Purity
99.32
Solubility
DMSO : 12.5 mg/mL (ultrasonic)
Smiles
NC1=NC=CC=C1C2=NC3=CC=C(C4=CC=CC=C4)N=C3N2C5=CC=C(C6(N)CCC6)C=C5
Molecular Formula
C27H24N6
Molecular Weight
432.52
Precautions
H315, H319, H320
References & Citations
[1]Lapierre JM, et al. Discovery of 3- (3- (4- (1-Aminocyclobutyl) phenyl) -5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl) pyridin-2-amine (ARQ 092) : An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor. J Med Chem. 2016 Jul 14;59 (13) :6455-69.|[2]Devki Nandan, et al. Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PLoS One. 2018 Nov 6;13 (11) :e0206920.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Akt1; Akt2; Akt3; Leishmania

Popular Products